glutathione depletion Summary. Hypoxia, ROS and increase PRIMA-1 Neurodegeneration due to glutathione depletion

In September 2023, the FDA added BPC-157 to its Category 2 list of bulk drug substances under its Interim Policy on Compounding, meaning 503A compounding pharmacies and 503B outsourcing facilities are barred from using it in compounded preparations

Mechanism of Action 5-Amino-1MQ operates by inhibiting nicotinamide N-methyltransferase (NNMT), an enzyme associated with metabolic regulation within adipose tissue

Caution is warranted when using the peptide alongside other compounds, particularly those affecting metabolism or cardiovascular function

With repeated exposure at each dose level, the nausea response decreases

BPC-157 occupies a unique position attempting to achieve lasting benefit through tissue repair and sphincter restoration without surgical intervention